Mesothelioma—from Diagnosis to Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 May 2024 | Viewed by 1637
Special Issue Editor
Interests: lung cancer; malignant mesothelioma; chemotherapy; immunotherapy; asbestos-related diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that develops in the mesothelial cell layer of the pleura. Exposure to asbestos is a well-known cause of MPM. The global incidence of MPM has continuously risen along with the widespread industrial use of asbestos. Recent progress in basic research and clinical practice has demonstrated some crucial evidence relating to molecular pathogenesis and perspectives on potential therapeutic approaches leading to promising treatment. In particular, immunotherapy has opened a door to favorable treatment options for patients with advanced diseases.
This Special Issue is designed to provide a state-of-the-art overview of recent scientific research on mesothelioma, including the pathogenesis, diagnosis, and management of MPM.
This Special Issue will identify the unmet needs in the diagnosis and management of MPM based on a combination of original research and review papers.
Topics will include:
The pathogenesis of MPM;
The challenge in the diagnosis of MPM;
The role of surgery in the treatment of MPM;
Systemic therapy of MPM including immunotherapy and/or chemotherapy;
Supportive care in MPM.
Dr. Nobukazu Fujimoto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- asbestos
- BAP-1
- CAR-T
- CTLA-4
- immunotherapy
- mesothelioma
- PD-1
- PD-L1
